ELISA - LübEcker longitudinal study on Infections with SARS-CoV-2 (COVID-19)

ELISA - LübEcker longitudinal study on Infections with SARS-CoV-2 (COVID-19) - ELISA

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00023418

Enrollment

3000

Registered

2020-10-28

Start date

2020-05-06

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID 19

Interventions

Group 1: Population cohort and risk cohort (people with a lot of contact with other people) with repetitive interviewing and testing of Nasopharyngeal swab PCR and virus sequencing Serum antibody tes

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: persons of full age, informed consent has been obtained

Exclusion criteria

Exclusion criteria: Underage person and persons who are unable to give their consent are not included in the study.

Design outcomes

Primary

Measure	Time frame
What is the prevalence of COVID-19 (current and past infections) and SARS-CoV-2 infection rates in a defined population-based population in Lübeck and how many new infections occur in the course of time? (repetitive PCRs and antibody tests)	—

Secondary

Measure	Time frame
What are the COVID-19 prevalence and SARS-CoV-2 infection rates in defined Risk groups and how many new infections occur in the course of the disease? How does COVID-19 progress and how many SARS-CoV-2 infections remain "asymptomatic"? How do SARS-CoV-2 detection, antibody profiles, adaptive cellular immune response and COVID-19 diseases; what conclusions can be drawn for draw the longevity of an immunity? Is it possible to detect the virus in urine? Can metabolites be identified that are related to the clinical course (e.g. severity of disease, duration of antibody occurrence) correlate? Can COVID-19 symptoms be distinguished from those of other influenza infections? Like Do olfactory and gustatory senses behave in the presence of SARS-CoV-2 detection? Are there any indications of long-term effects of the disease? Can parameters be identified in the computer model that influence the (regional) Explain the spread/the risk?	—

Measure

Time frame

What are the COVID-19 prevalence and SARS-CoV-2 infection rates in defined Risk groups and how many new infections occur in the course of the disease? How does COVID-19 progress and how many SARS-CoV-2 infections remain "asymptomatic"? How do SARS-CoV-2 detection, antibody profiles, adaptive cellular immune response and COVID-19 diseases; what conclusions can be drawn for draw the longevity of an immunity? Is it possible to detect the virus in urine? Can metabolites be identified that are related to the clinical course (e.g. severity of disease, duration of antibody occurrence) correlate? Can COVID-19 symptoms be distinguished from those of other influenza infections? Like Do olfactory and gustatory senses behave in the presence of SARS-CoV-2 detection? Are there any indications of long-term effects of the disease? Can parameters be identified in the computer model that influence the (regional) Explain the spread/the risk?

—

Countries

Germany

Contacts

Public ContactAlexander Katalinic

Universität zu Lübeck, Institut für Sozialmedizin und Epidemiologie

alexander.katalinic@uni-luebeck.de+49 451 50051200

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 12, 2026